Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Copyright © 2020. The Korean Association of Immunologists..
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not develop durable antitumor responses after ICI therapy due to an ephemeral reversal of T-cell dysfunction. As co-stimulatory receptors play key roles in regulating the effector functions of T cells, activating co-stimulatory pathways may improve checkpoint inhibition efficacy, and lead to durable antitumor responses. Here, we review recent advances in our understating of co-stimulatory receptors in cancers, providing the necessary groundwork for the rational design of cancer immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Immune network - 20(2020), 1 vom: 02. Feb., Seite e3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeong, Seongju [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer, Immunotherapy |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4110/in.2020.20.e3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307468496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307468496 | ||
| 003 | DE-627 | ||
| 005 | 20231225125629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4110/in.2020.20.e3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1024.xml |
| 035 | |a (DE-627)NLM307468496 | ||
| 035 | |a (NLM)32158591 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeong, Seongju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020. The Korean Association of Immunologists. | ||
| 520 | |a Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not develop durable antitumor responses after ICI therapy due to an ephemeral reversal of T-cell dysfunction. As co-stimulatory receptors play key roles in regulating the effector functions of T cells, activating co-stimulatory pathways may improve checkpoint inhibition efficacy, and lead to durable antitumor responses. Here, we review recent advances in our understating of co-stimulatory receptors in cancers, providing the necessary groundwork for the rational design of cancer immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer, Immunotherapy | |
| 650 | 4 | |a Costimulatory T-cell receptors | |
| 650 | 4 | |a T-Lymphocytes | |
| 700 | 1 | |a Park, Su-Hyung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immune network |d 2009 |g 20(2020), 1 vom: 02. Feb., Seite e3 |w (DE-627)NLM19466144X |x 1598-2629 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:1 |g day:02 |g month:02 |g pages:e3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4110/in.2020.20.e3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 1 |b 02 |c 02 |h e3 | ||